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Abstract 
Neuroticism has long been associated with psychopathology and there is increasing evidence that 
this trait represents a shared vulnerability responsible for the development and maintenance of a 
range of common mental disorders. Given that neuroticism may be more malleable than 
previously thought, targeting this trait in treatment, rather than its specific manifestations (e.g., 
anxiety, mood and personality disorders), may represent a more efficient and cost-effective 
approach to psychological treatment. The goals of the current manuscript are to (1) review the 
role of neuroticism in the development of common mental disorders, (2) describe the evidence of 
its malleability, and (3) review interventions that have been explicitly developed to target this 
trait in treatment.  Implications for shifting the focus of psychological treatment to underlying 
vulnerabilities, such as neuroticism, rather than on the manifest symptoms of mental health 
conditions, are also discussed. 
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Addressing Neuroticism in Psychological Treatment 
Neuroticism is typically defined as the tendency to experience frequent and intense 
negative emotions in response to various sources of stress. While the emotions considered within 
the purview of this trait include the range of negative affect (e.g., fear, irritability, anger, 
sadness), the greatest focus has been on the experience of anxious and depressive mood. The 
perception that the world is a dangerous and threatening place also accompanies this exaggerated 
negative emotionality, along with beliefs about one’s lack of agency to handle challenging 
events. Manifestations of this trait may also include heightened focus on criticism, either self-
generated or from others, as confirming a general sense of inadequacy and perceptions of lack of 
control over salient events (Barlow, 2002; Barlow, Sauer-Zavala, Carl, Bullis, & Ellard, 2014; 
Clark & Watson, 2008; Eysenck, 1947; Goldberg 1993).  
Barlow and colleagues (Barlow, Ellard, Sauer-Zavala, Bullis, & Carl, 2014) have 
forwarded a model to account for the development of neuroticism informed by an interaction of 
biological and psychological vulnerabilities. To summarize, the general biological risk is 
evidenced by high heritability estimates (40% to 60%) for this trait (e.g. Bouchard & Loehlin, 
2001; Clark, Watson, & Mineka, 1994; Kendler, Prescott, Myers, & Neale, 2003), with 
genetically mediated neuroticism linked to the neurobiological tendency for heighted reactivity 
in emotion-generating structures, including amygdala hyperexcitability, and reduced inhibitory 
control by prefrontal systems (Keightley et al., 2003; Stein, Simmons, Feinstein, & Paulus, 2007; 
Westlye, Bjornebekk, Grydeland, Fjell, & Walhovd, 2011). These neural circuits are also 
influenced by a general psychological vulnerability that includes stressful, traumatic, or related 
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developmental experiences during childhood, cultivating the perception that life events are 
unpredictable and uncontrollable (Gunnar & Quevedo, 2007; Lanius, Frewen, Vermetten, & 
Yehuda, 2010; Rosen & Schulkin, 1998). Taken together, these general biological and 
psychological vulnerabilities build upon each other to produce the neurotic phenotype. 
Importantly, these interacting vulnerabilities were originally described as part of an etiological 
model for trait anxiety and emotional disorders more generally (Barlow, 2000, 2002), suggesting 
that a neurotic temperament may be a necessary component for the development of a range of 
psychological conditions. In fact, all the temporal covariance among the Diagnostic and 
Statistical Manual (DSM; American Psychiatric Association, 2013) constructs of depression and 
several anxiety disorders can be accounted for by neuroticism (Brown, 2007). 
Neuroticism has been associated with a wide range of public health problems (see: 
Lahey, 2009). For example, this trait strongly predicts a variety of mental disorders as well as 
comorbidity amongst them (Clark, Watson, Mineka, 1994; Khan, Jacobson, Gardner, Prescott, & 
Kendler, 2005; Krueger & Markon, 2006; Sher & Trull, 1994; Weinstock & Whisman, 2006), 
including personality disorders (Henriques-Calado et al., 2014; Sauer-Zavala & Barlow, 2014; 
Widiger, Verheul, & van den Brink, 1999; Widiger, Costa, & McCrae, 2002). Neuroticism has 
also been associated with a range of physical problems including cardiovascular disease, eczema, 
asthma, and irritable bowel syndrome (Brickman, Yount, Blaney, Rothberg, & De-Nour, 1996; 
Smith & MacKenzie, 2006; Suls & Bunde, 2005). Additionally this trait predicts treatment 
seeking and response to treatment for both mental disorders and general health concerns 
(Shipley, Weiss, Der, Taylor, & Deary, 2007). Considering these public health consequences, it 
is not surprising that the economic cost of this trait exceeds the cost of common mental disorders 
(Cuijpers, Smit, Penninx, de Graaf, and Beekman; 2010).  
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A discussion of the public health costs associated with neuroticism prompts consideration 
of how this trait may be addressed. As noted above, the transactional relationship between 
genetic and environmental inputs for neuroticism suggests that the inherited contributions of this 
trait may serve as a predisposition, but not a mandate. This opens the question of whether 
neuroticism can be treated directly, rather than separately targeting each manifestation of this 
trait in the form of separate mental health and physical disorders. This approach is consistent 
with National Institute of Mental Health’s Research Domain Criteria (RDoC) initiative that 
challenges researchers to look beyond diagnoses to identify core processes implicated in the 
development and maintenance of symptoms across a range of disorders (Insel, 2010). Targeting 
neuroticism itself may represent a more efficient and cost-effective means of addressing the wide 
swath of public health problems associated with it. 
Malleability of Neuroticism 
Although personality traits have long been considered stable and inflexible across time 
(APA, 2013), there is increasing evidence that neuroticism may be more malleable than 
originally believed. For example, in a review of the literature regarding the stability of 
personality disorders, Clark (2009) notes that the traits associated with these diagnoses do 
change slowly over time, with the greatest shifts occurring in the behavioral manifestations of 
these traits. Further, longitudinal studies of the general population also show gradual age-related 
decreases in neuroticism and related constructs (i.e., internalizing) that continue into old age 
(Eaton, Krueger, & Oltmanns, 2011; Roberts, Walton & Viechtbauer, 2006; Roberts & 
Mroczeck, 2008). Overall, this pattern of results suggests that, on average , neuroticism 
decreases across time; however, when change in neuroticism has been examined at the 
individual-level using growth modeling (Mroczek & Spiro, 2003), there appears to be great 
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variability in the extent of change, with some people maintaining a stable level of this trait and 
others changing considerably (Helson, Jones, & Kwan, 2002; Small, Hertzog, Hultsch, & Dixon, 
2003). Indeed, there is evidence to suggest that individuals with higher initial levels of 
neuroticism tend to show less change in this dimension over time, and conversely, individuals 
with lower initial levels of neuroticism tend to evidence greater change (Brown, 2007).  
Change in neuroticism has also been explored in the context of individuals seeking 
treatment for DSM disorders.  For example, in a study that tracked 41 individuals with MDD 
across 8 months (most of whom received some kind of treatment during this time), neuroticism 
remained stable, despite changes in clinical state (Eaton, Krueger, & Oltmanns, 2011). 
Specifically, neuroticism displayed the same high level of temporal stability in individuals who 
no longer met criteria for MDD as it did in the subgroup of participants who were depressed at 
both assessment points. In contrast, others have indeed found changes in neuroticism as a 
function of time and treatment. For example, Brown and colleagues (2007; Brown & Barlow, 
2009) examined the temporal course of neuroticism and its relationship to the DSM–IV disorder 
constructs of depression, social anxiety disorder, and generalized anxiety disorder in a large 
sample (N = 606) of outpatients with these disorders. Participants were assessed at intake and 
then reassessed at 1-year and 2-year follow-ups with the majority (76%) of patients receiving 
some kind of treatment (of varying quality and duration) during the follow-up period. As 
expected, DSM-IV disorder constructs improved significantly over time and other 
temperamental variables (e.g., extraversion) remained stable; neuroticism, however, evidenced 
the greatest amount of temporal change and was the dimension associated with the largest 
treatment effect.  
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In addition to studies exploring the malleability of neuroticism in treatment-seeking 
samples where the treatment received was unspecified, changes in neuroticism have also been 
examined in the context of specific interventions. First, Kring, Persons, and Thomas (2007) 
assessed the degree to which neuroticism (described as negative affectivity in this study) and 
symptoms of depression and anxiety changed across a course of cognitive-behavioral therapy. 
Results suggest that neuroticism, as well as symptoms of depression and anxiety, decreased 
following the 12-week course of treatment; unfortunately, it is difficult to determine whether 
change in temperament is driving change in symptoms or vice versa as the study did not include 
multiple repeated measures of these variables. Additionally, in a large randomized-controlled 
trial of cognitive therapy (CT) compared to placebo for adults with major depressive disorder 
(Tang, et al, 2009), CT produced greater changes in both neuroticism and extraversion than 
placebo. However, contrary to Brown’s (2007) results, after controlling for changes in depressive 
symptoms, the effect of CT on these temperamental variables remained significant only for 
extraversion. Finally, levels of neuroticism did not appear to change significantly following a 
course of treatment with dialectical behavior therapy for individuals with borderline personality 
disorder (Davenport, Bore, & Campbell, 2010). 
It is possible that the inconsistent results described above are due to the fact that the 
decreases in neuroticism found in some studies may be attributable to the overlap between 
measures of temperament and symptomatic measures of anxiety and depression, resulting in an 
overestimation of temperamental change known as mood-state distortion (Clark, Vittengl, Kraft, 
& Jarrett, 2003; Jylha & Isometsa, 2006; Widiger, Verheul, & van den Brink, 1999). In other 
words, the measurement of neuroticism consists of some combination of stable temperamental 
variance and variability attributable to generalized distress that is apt to covary with temporal 
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fluctuations in the severity of disorders. While this could be a compelling explanation of the 
diverse findings with regard to temperamental malleability, results from a recent study suggest 
that measures of neuroticism (and extraversion) primarily capture true temperamental variance 
even in individuals with emotional disorders (Naragon-Gainey, Gallagher, & Brown, 2013). 
Additionally, a number of longitudinal studies have controlled for the periodic occurrence of 
anxious or depressive symptoms and still found neuroticism to act independently in predicting 
anxiety and mood (Lahey, 2009; Spijker, 2007). In fact, while neuroticism predicts the course 
DSM disorders, with higher levels of this trait reflecting less change in symptoms across time, 
the converse does not appear to occur; that is, initial levels of DSM disorders do not predict 
changes in temperament over time (Brown & Rosellini, 2011; Gershuny & Sher, 1998; Kasch et 
al., 2002; Meyer, Johnson, & Winters, 2001). 
In sum, there appears to be evidence that neuroticism is subject to change slowly across 
the course of the lifespan (e.g., Clark, 2009; Roberts & Mroczeck, 2008), however the degree to 
which this and other temperamental variables are malleable in response to treatment remains 
unclear. The studies described above examined changes in neuroticism in the context of 
naturalistic treatments or treatments targeting disorder-specific symptoms and have yielded 
mixed results. Indeed, the research reviewed raises questions about the mechanisms through 
which neuroticism changes and whether directly targeting this trait in treatment would lead to 
more definitive results.  
Treatment of Neuroticism 
Most studies that have examined changes in temperament in response to psychological 
treatment, including the studies described in the previous section, utilize interventions that were 
not specifically designed to target neuroticism itself, but rather to address DSM disorder 
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symptoms. It is possible that the lack of a priori specification regarding how and why these 
treatments impact temperament may have led to the mixed findings on the responsiveness of 
neuroticism to treatment; in other words, some interventions may be more suited to address 
neuroticism than others. Emerging research, however, suggests that when neuroticism is 
addressed directly with interventions explicitly designed to target it, change on this construct is 
more robust. This literature, including specific interventions for neuroticism and the putative 
pathways through which they target it, are reviewed below. 
Most of the studies that examine interventions specifically designed to target 
temperament have come from the psychopharmacology literature (for review, see: Ilieva, 2015; 
Soskin, Carl, Alpert & Fava, 2012). Serotonergic drug agents (i.e., selective serotonin reuptake 
inhibitors) appear to produce dampening effects on neuroticism (Fu et al., 2004; Harmer, 
Mackay et al., 2006; Harmer, O’Sullivan et al., 2009; Murphy, Yiend, Lester, Cowen, & Harmer, 
2009; Quilty, Meusel, & Bagby, 2008), while catecholaminergic (i.e., 
noradrenergic/dopaminergic) drugs enhance extraversion (McCabe et al., 2010; Tomarken, 
Dichter, Freid, Addington, Shelton, 2004). Clear hypotheses relating these agents to 
neurobiological changes have been forwarded that underscore their effect on temperament. For 
example, serotonergic agents likely produce dampening of neuroticism due to their ability to 
decrease hyperreactivity of the amygdala in response to fear-inducing stimuli and to inhibit 
dopaminergic neurotransmission in areas of the prefrontal cortex. In contrast, catecholaminergic 
agents may be associated with increased extraversion due to their ability upregulate 
noradrenergic and dopaminergic neurotransmission, particularly within the mesolimbic reward 
circuitry (Soskin et al., 2012). The fact that specific pharmacological agents display preferential 
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effects on dimensions of temperament suggests that that there may be utility in designing 
behavioral treatments to selectively address temperamental variables.   
Currently, there are few behavioral interventions that are explicitly designed to target 
temperament. One of the first examples of a treatment developed to address temperamental 
vulnerabilities, rather than psychological symptoms, is Rapee’s (2005) intervention for 
behavioral-inhibited children; the goal of addressing behavioral inhibition was to prevent the 
onset of future anxiety disorders. The program focuses on parenting training in order to minimize 
augmentation of the child’s biological nature through environmental interactions and includes 
psychoeducation about the nature of anxiety, traditional cognitive-behavioral strategies (i.e. 
exposure and cognitive restructuring) directed toward personal concerns, and training in behavior 
management techniques that prevent an overprotective parenting style. Results from randomized 
controlled trials (Rapee, Kennedy, Ingram, Edwards & Sweeney, 2005; Rapee, Kennedy, 
Ingram, Edwards & Sweeney, 2010) suggest that this program is indeed successful at preventing 
anxiety disorders, however when the focus is on temperament a brief version of this program did 
not appear to produce significant changes in behavioral inhibition measured via parent report or 
laboratory observation (Rapee et al.; 2010). However, a more intensive version with higher risk 
children indeed led to significantly greater reductions in this trait compared to those who did not 
receive the treatment (Kennedy, Rapee, & Edwards, 2009). Differences among groups increased 
over time, leading Rapee et al. (2010) to speculate that more intensive interventions directed at 
temperament might produce an increasing trajectory of change in temperament compared to 
addressing more surface-level disorder symptoms. 
The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP; Barlow 
et. al., 2011) represents another example of an intervention explicitly developed to address 
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temperamental vulnerabilities, in this case neuroticism, associated with common mental health 
conditions. As noted above, neuroticism is implicated in the development of the range of anxiety, 
depressive, and related disorders (e.g., somatic symptom disorders, trauma-related disorders), 
also known as “emotional disorders” (Barlow, 2002) given the role of intensive  emotional 
experience in their development. In addition to the frequent experience of negative emotions, 
emotional disorders are also characterized by aversive reactions to emotional experiences, 
leading to problematic efforts to escape or avoid them (see: Barlow, Sauer-Zavala, Carl, Bullis, 
& Ellard, 2014; Sauer-Zavala & Barlow, 2014). In order to address neuroticism, the UP consists 
of six core treatment modules aimed at extinguishing distress in response to the experience of 
strong emotions. The rationale for this aim is that with fewer aversive reactions to negative 
emotions when they occur, reliance on avoidant emotion regulation strategies that exacerbate 
symptoms is reduced, which in turn leads to less frequent and intense negative emotions over 
time. This approach has shown efficacy for the range of anxiety and unipolar depressive 
disorders (Barlow et al., in preparation; Boswell, Anderson, & Barlow, 2014; Ellard, Fairholme, 
Boisseau, Farchione, & Barlow, 2010; Farchione et al., 2012) and there is preliminary support 
for the use of the UP with borderline personality disorder (Sauer-Zavala, Bentley, & Wilner, 
2015), bipolar disorder (Ellard, Deckersbach, Sylvia, Nierenberg, & Barlow, 2012) and 
posttraumatic stress disorder (PTSD; Gallagher, 2015). 
The modules of the UP have been described in detail elsewhere (e.g., Payne, Ellard, 
Farchione, Fairholme, & Barlow, 2014); however a summary of how the six core modules 
cultivate a more accepting stance toward emotional experiences is described here. First, by 
providing information about the adaptive, functional nature of emotions in the psychoeducation 
module (core module 1), patients begin to cultivate the stance that emotions provide useful 
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information and should not be avoided. Next, patients receive instruction on how to engage 
willingly, versus with avoidance, with their emotional experiences via mindfulness training (core 
module 2); specifically, patients are taught the benefits of a present-focused, non-judgmental 
attitude toward their emotions through three complimentary experiential exercises.   
Following the presentation of the UP orientation (e.g., cultivating a more accepting 
stance toward emotions), patients are taught specific skills that map onto three interacting 
components of an emotional experience (i.e., thoughts, behaviors and physical sensations). First, 
patients are encouraged to be more flexible in the way they appraise emotion-eliciting situations 
(core module 3); patients are instructed to question the automaticity of interpretations, rather than 
to change maladaptive cognitions – in line with the UP’s emphasis on acceptance. The following 
module, countering emotional behaviors (core module 4), involves the identification of patient-
specific avoidance behaviors that hinder full exposure to strong emotions. Patients are then 
instructed to act counter to their emotion-driven behavioral urges by engaging in activities that 
may put them in contact with strong emotions in the short-term.  Next, patients cultivate a greater 
tolerance of physical sensations through interoceptive exercises (e.g., hyperventilation, breathing 
through a thin straw) that deliberately provoke the physiological feelings associated with strong 
emotions (core module 5). Finally, treatment culminates with emotion exposures (core module 6) 
in which patients engage in a series a series of activities that elicit strong or uncomfortable 
emotions. Through this practice, patients’ aversive reactions to emotions are gradually 
extinguished via new learning that emotions are temporary and can be tolerated.  
There is evidence to suggest that the approach to targeting temperament utilized in the 
UP indeed leads to changes in neuroticism (Carl, Gallagher, Sauer-Zavala, Bentley, & Barlow, 
2013). In the context of a small randomized-controlled trial (i.e., Farchione et al., 2012), the UP 
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produced small to moderate effects on measures of neuroticism from pre- to post-treatment 
compared with a waitlist group, and these changes were maintained at the six-month follow-up 
assessment point. In addition, these changes in neuroticism predicted decreased anxiety and 
depressive symptoms and reductions in functional impairment. Overall, the results of this 
investigation suggest in a preliminary manner that neuroticism can be successfully targeted in 
treatment and that reductions in this temperamental vulnerability also affect treatment outcomes.  
More recently, Armstrong and Rimes (2016) conducted a pilot study examining the effect 
of mindfulness-based cognitive therapy (MBCT; Segal et al., 2002) that had been explicitly 
modified to directly target levels of neuroticism. The version of MBCT used in this study 
included references to neuroticism-related constructs, rather than depression-related themes. For 
example, session 1 covered stress-reactivity by introducing the fight-or-flight response, the role 
of the hypothalamic-pituitary-adrenal axis, and unhelpful ways of responding to stress (i.e., 
overthinking and avoiding).  Session 2 involved discussion about the relationship between 
thoughts and feelings as well as common interpretation biases, and in session 3, genetic and 
environmental contributions that make an individual susceptible to stress are discussed.  In 
session 4 patients learn about the long- and short-term consequences of avoiding stress-eliciting 
situations and session 5 extends this discussion by presenting the notion that avoiding such 
situations leads to increased suffering. Sessions 6 and 7 cover additional maladaptive, neurotic 
responses to stress including overthinking and self-criticism. Finally, session 8 ties together the 
skills for “stress management” that had been learned previously in the treatment. Following 8-
weeks of treatment, participants in the MBCT condition demonstrated significantly greater 
reductions in neuroticism than participants in the internet-based self-help control condition.   
Conclusions 
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Contrary to theoretical conceptions of personality, research suggests that neuroticism 
may be malleable over time or in response to treatment; however, such findings have been 
mixed, indicating that additional work is necessary to identify the specific conditions that impact 
temperament. Interventions that were explicitly developed to target neuroticism appear to have 
the most consistent effects on this trait. Rapee and colleagues’ (2005, 2010) work with 
behaviorally inhibited children addresses the neuroticism by targeting the environmental factors 
(e.g., parenting styles) that contribute to the general psychological vulnerability (e.g., the belief 
that the world is a dangerous, uncontrollable place; Barlow et al., 2014) necessary for this trait’s 
development. In adults, both the UP and neuroticism-focused MCBT address neuroticism by 
targeting the aversive, avoidant reactions to emotions that, paradoxically, increase the frequency 
and intensity of future negative emotions (Armstrong & Rimes, 2016; Carl et al., 2013).  In sum, 
these efforts provide preliminary support for the notion that psychological interventions can 
indeed address temperamental vulnerabilities, and that such improvements are associated with a 
range of beneficial treatment outcomes (Carl et al., 2013; Farchione et al., 2012; Kennedy et al., 
2009).  
There are several advantages to shifting to focus of treatment to core temperamental 
vulnerabilities, rather than focusing disorder-specific symptoms. First, the rates of comorbidity 
amongst common mental disorders, including emotional disorders and personality disorders, are 
quite high (Grant et al., 2008; Zanarini et al., 1998).  Rather than prioritizing treatment of one 
condition over another, an intervention focused on a shared vulnerability (e.g., neuroticism) 
could lead to simultaneous improvement across symptoms of all co-occurring disorders. 
Additionally, separate treatments for each Diagnostic and Statistical Manual diagnosis places a 
burden on practitioners to receive training to competently provide these interventions; targeting 
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common temperamental mechanisms may reduce the number of treatments, increasingly the 
likelihood that empirically-supported treatments will be more widely disseminated.  
It is important to note that all three behavioral treatments developed to target neuroticism 
consist of multiple components. Given that they have each been tested only in their entirety, it is 
unclear whether each component contributes equally to the observed reductions in neuroticism. 
Future research should explore the unique contributions of each skill included in these treatment 
packages in order to identify the components that lead to the most robust and efficient changes in 
temperament. In addition, future research must also explore the possibility of intervention before 
a neurotic temperament fully develops. In fact, there is evidence to suggest that behavioral 
inhibition can be detected as early as 4 months old from crying and salivary cortisol in response 
to novel stimuli (Moehler, Kagan, Oekers-Ax, et al., 2008; Reck, Muller, Tietz, & Molher, 
2013). The animal literature provides insight into strategies that may be useful in preventing 
neuroticism; for example, exposing newborn rats to novel environments for 3 minutes a day 
resulted in less behavioral inhibition (defined as time spent in exploration after weaning) 
compared to newborn rats that stayed in their home cage (Tang, Reeb-Southerland, Romeo, & 
McEwen, 2012). As such, it is important to identify early biological and behavioral markers that 
may indicate a vulnerability for the development of a neurotic temperament and that could serve 
as triggers for intervention.  
In sum, treatments developed to directly target neuroticism indeed appear to impact this 
trait. However, to our knowledge only three behavioral trials have been published with the aim 
of impacting temperamental factors, despite the advantages conferred by targeting shared 
vulnerabilities instead of disorder symptoms. Future research should not only continue to 
develop treatment for temperament, but also explore which components included in these 
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treatments for neuroticism are the most successful at reducing this trait, as well as how early 
interventions can occur.  
 
 
 
 
 
References 
 
American Psychiatric Association, (2013). Diagnostic and statistical manual of mental disorders 
(5th ed.). Washington, DC: Author. 
Armstrong, L. & Rimes, K.A. (in press). Mindfulness-based cognitive therapy for neuroticism 
(stress vulnerability): A pilot randomized study, Behavior Therapy. doi: 
10.1016/j.beth.2015.12.005 
Barlow, D.H. (2000). Unraveling the mysteries of anxiety and its disorders from the perspective 
of emotion theory. American Psychologist, 55, 1247-1263. doi:10.1037/0003-
066X.55.11.1247 
Barlow, D.H. (2002). Anxiety and its disorders: The nature and treatment of anxiety and panic 
(2nd ed.). New York: Guilford Press. 
Barlow, D.H., Ellard, K.K., Fairholme, C., Farchione, T.J., Boisseau, C., Allen, L., &  
Ehrenreich-May, J. (2011). Unified Protocol for the Transdiagnostic Treatment of 
Emotional Disorders. New York, NY: Oxford University Press.  
Barlow, D.H., Farchione, T.J., Bullis, J.R., Gallagher, M.W., Latin, H., Sauer-Zavala, S.,  
Bentley, K.H., Thompson-Hollands, J., Conklin, L., Boswell, J.F., Ametaj, A.A., Carl,  
J.R., Boettcher, H.T., & Cassiello-Robbins, C. (in preparation). Equivalence evaluation of  
the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders compared to  
diagnosis-specific CBT for anxiety disorders. 
THE TREATMENT OF NEUROTISCM 17 
Barlow, D.H., Sauer-Zavala, S., Carl, J.R., Bullis, J.R., & Ellard, K.K. (2014). The nature, 
assessment, and treatment of neuroticism: Back to the Future? Clinical Psychological 
Science, 2(3), 344-365. doi: 10.1177/2167702613505532 
Bouchard, T.J., & Loehlin, J.C. (2001). Genes evolution, and personality. Behavior Genetics, 31, 
243-273. doi: 10.1023/A:1012294324713 
Boswell, J. F., Anderson, L. M., & Barlow, D. H. (2014). An idiographic analysis of change  
 processes in the unified transdiagnostic treatment of depression. Journal of Consulting  
 and Clinical Psychology, 82(6), 1060.  
Brickman, A.L., Yount, S.E., Blaney, N.T., Rothberg, S.T., & De-Nour, A. (1996). Personality 
traits and long-term health status: The influence of neuroticism and conscientiousness on 
renal deterioration in Type-1 diabetes. Psychosomatics: Journal of Consultation Liaison 
Psychiatry, 37, 459-468. 
Brown, T. A. (2007). Temporal course and structural relationships among dimensions of  
temperament and DSM–IV anxiety and mood disorder constructs. Journal of Abnormal 
Psychology, 116, 313–328. 
Brown, T.A. & Barlow, D.H. (2009). A proposal for a dimensional classification system based 
on the shared features of the DSM-IV anxiety and mood disorders: Implications for 
assessment and treatment. Psychological Assessment, 21(3), 256-271. 
Brown, T. A. & Rosellini, A. J. (2011). The direct and interactive effects of neuroticism and life 
stress on the severity and longitudinal course of depression. Journal of Abnormal 
Psychology, 120, 844-856.   
Carl, J.R., Gallagher, M.W., Sauer-Zavala, S.E., Bentley, K.H., & Barlow, D.H. (2014). A  
preliminary examination of the effects of the Unified Protocol on temperament. 
THE TREATMENT OF NEUROTISCM 18 
Comprehensive Psychiatry, 55(6), 1426-1434.  
Clark, L. (2009). Stability and change in personality disorder. Current Directions in  
Psychological Science, 18, 27-31. 
Clark, L., Vittengl, J., Kraft, B., & Jarrett, D. (2003). Separate personality traits from states to  
predict depression. Journal of Personality Disorders, 17, 152-172. 
Clark, L.A. & Watson, D. (2008). Temperament: An organizing paradigm for trait psychology. 
In Oliver & Robins (eds.) Handbook of Personality: Theory and Research (3rd ed.). New 
York: Guilford. 
Clark, L. A., Watson, D., & Mineka, S. (1994). Temperament, personality, and the mood and 
anxiety disorders. Journal of Abnormal Psychology, 103, 103-116. doi: 10.1037/0021-
843X.103.1.103 
Cuijpers, P., Smit, F., Penninx, B.W. J. H., de Graaf, R., ten Have, M. & Beekman, A.T. 
F.(2010). Economic costs of neuroticism: A population based study. Archives of General 
Psychiatry, 67, 1086-1093. doi: 10.1016/j.ypsy.2010.11.021 
Davenport, J., Bore, M., & Campbell, J. (2010). Changes in personality in pre-and post-
dialectical behaviour therapy borderline personality disorder groups: A question of self-
control. Australian Psychologist, 45(1), 59-66. 
Eaton, N., Krueger, R., & Oltmanns, T. (2011). Aging and the structure and long-term stability  
of the internalizing spectrum of personality and psychopathology. Psychology and Aging, 
26, 987-993. 
Ellard, K. K., Fairholme, C. P., Boisseau, C. L., Farchione, T. J., & Barlow, D. H. (2010). 
Unified protocol for the transdiagnostic treatment of emotional disorders: Protocol 
THE TREATMENT OF NEUROTISCM 19 
development and initial outcome data. Cognitive and Behavioral Practice, 17, 88-101. 
doi: 10.1016/j.cbpra.2009.06.002 
Ellard, K. K., Deckersbach, T., Sylvia, L. G., Nierenberg, A. A., & Barlow, D. H. (2012).  
 Transdiagnostic treatment of bipolar disorder and comorbid anxiety with the Unified  
 Protocol: A clinical replication series. Behavior Modification, 36(4), 482-508.  
Eysenck, J.J. (1947). Dimensions of Personality. Oxford, England: Kegan Paul.  
Farchione, T.J., Fairholme, C.P., Ellard, K.K., Boisseau, C.L., Thompson-Hollands, J., Carl, J., 
Gallagher, M.W., & Barlow, D.H. (2012) The Unified Protocol for the Transdiagnostic 
Treatment of Emotional Disorders: A randomized controlled trial. Behavior Therapy, 43, 
666-678. 
Fu, C.H., Williams, S.C., & Cleare, A.J. (2004). Attenuation of the neural response to sad faces  
in major depression by antidepressant treatment: A prospective, event-related functional 
magnetic resonance imaging study. Archives of General Psychiatry, 61, 877–889. 
Gallagher, M. W. (2015). Unified Protocol for Posttraumatic Stress Disorder. Book chapter in 
preparation.   
Gershuny, B. S., & Sher, K. J. (1998). The relation between personality and anxiety: findings 
from a 3-year prospective study. Journal of Abnormal Psychology, 107, 252-262. 
Goldberg, L. (1993). The structure of phenotypic personality traits. American Psychologist, 48, 
26-34. doi: 10.1037/0003-066X.48.12.1302 
Grant, B., Chou, S., Huang, B., Stinson, F., Saha, T., et al. (2008). Prevalance, correlates,  
disability, and comorbidity of DSM-IV borderline personality disorder: Results from the  
Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Journal of  
Clinical Psychiatry, 69, 533-545. doi: 10.4088/JCP.v69n0404 
THE TREATMENT OF NEUROTISCM 20 
Gunnar, M., & Quevedo, K. (2007). The neurobiology of stress and development. Annual Review 
of Psychology, 58, 145-173. doi: 10.1146/annurev.psych.58.110405.085605 
Harmer, C.J., Mackay, C.E., Reid, C.B., Cowen, P.J., & Goodwin, G.M. (2006) Antidepressant  
drug treatment modifies the neural processing of nonconscious threat cues. Biologial  
Psychiatry, 59, 816–820. 
Harmer, C.J., O'Sullivan, U., Favaron, E., Massey-Chase, R., Ayres, R., Reinecke, A., . . .  
Cowen, P.J. (2009). Effect of acute antidepressant administration on negative affective 
bias in depressed patients. American Journal of Psychiatry, 166, 1178-1184. 
Helson, R., Jones, C., & Kwan, V.S. (2002). Personality change over 40 years of adulthood: 
Hierarchical linear modeling analyses of two longitudinal samples. Journal of 
Personality and Social Psychology, 83, 752-766. 
Henriques-Calado, J., Duarte-Silva, M., Junqueira, D., Sacoto, C., & Keong, A. (2014). Five-
factor model personality domains in the prediction of Axis II personality disorders: An 
exploratory study in late adulthood women non-clinical sample. Personality and Mental 
Health, 8, 115-127.  
Ilieva, I. (2015). Enhancement of healthly personality through psychiatric medication: the 
influence of SSRIs on neuroticism and extraversion. Neuroethics, 8: 127-137. doi 
10.1007/s12152-014-9226-z 
Insel, T., Cuthbert, B., Garvey, J., Heinssen, R., Pine, D.S. ...Want, P. (2010). Research Domain 
Criteria (RDoC): Toward a new classification framework for research on mental 
disorders. American Journal of Psychiatry, 167, 748-751. 
Jylhä, P. & Isometsä, E. (2006). The relationship of neuroticism and extraversion to symptoms of 
anxiety and depression in the general population. Depression and Anxiety, 23, 281-289. 
THE TREATMENT OF NEUROTISCM 21 
Kasch, K. L., Rottenberg, J., Arnow, B. A., & Gotlib, I. H. (2002). Behavioral activation and 
inhibition systems and the severity and course of depression. Journal of Abnormal 
Psychology, 111, 589-597. 
Keightley, M.L., Seminowicz, D.A., Bagby, R.M., Costa, P.T., Fossati, P., & Mayberg, H. S. 
(2003). Personality influences limbic-cortical interactions during sad mood induction. 
NeuroImage, 20(4), 2031–2039. doi: 10.1016/j.neuroimage.2003.08.022 
Kennedy, S. J., Rapee, R. M., & Edwards, S. L. (2009). A selective intervention program for 
inhibited preschool-aged children of parents with an anxiety disorder: Effects on current 
anxiety disorders and temperament. Journal of the American Academy of Child and 
Adolescent Psychiatry, 48, 602-609. doi: 10.1097/CHI.0b013e31819f6fa9 
Kendler, K. S., Prescott, C. A., Myers, J., & Neale, M. C. (2003). The structure of genetic and 
environmental risk factors for common psychiatric and substance use disorders in men 
and women. Archives of General Psychiatry, 60, 929-937. doi: 
10.1001/archpsyc.60.9.929\n60/9/929  
Khan, A.A., Jacobson, K.C., Gardner, C.O., Prescott, C.A., & Kendler, K. (2005). Personality 
and comorbidity of common psychiatric disorders. British Journal of Psychiatry, 186, 
190-196. doi: 10.1192/bjp.186.3.190 
Krueger, R.F. & Markon, K.E. (2006). Reinterpreting comorbidity: A model-based approach to 
understanding and classifying psychopathology. Annual Review of Clinical Psychology, 
2, 111-133. 
Kring, A.,Persons, J., & Thomas, C. (2007). Changes in affect during treatment for depression  
and anxiety. Behaviour Research and Therapy, 45, 1753-1764. 
THE TREATMENT OF NEUROTISCM 22 
Lahey, B. B. (2009). Public health significance of neuroticism. American Psychologist, 64, 241-
256. 
Lanius, R. A., Frewen, P. A., Vermetten, E., & Yehuda, R. (2010). Fear conditioning and early 
life vulnerabilities: Two distinct pathways of emotional dysregulation and brain 
dysfunction in PTSD. European Journal of Psychotraumatology, 1. doi: 
10.3402/ejpt.v1i0.5467 
McCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010). Diminished neural processing of  
aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. 
Biological Psychiatry, 67, 439-445. 
Meyer, B., Johnson, S. L., & Winters, R. (2001). Responsiveness to threat and incentive in 
Bipolar Disorder: Relations of the BIS/BAS scales with symptoms. Journal of 
Psychopathology and Behavioral Assessment, 23, 133-143. 
Moehler, E., Kagan, J., Oelkers, Ax, R., Brunner, R., Poustka, L., Haffner, J., & Resch, F.  
(2008). Infant predictors of behavioural inhibition. British Journal of Developmental 
Psychology, 26, 145-150. 
Mroczek, D. & Spiro, A. (2003). Modeling intraindividual change in personality traits: Findings  
from the normative aging study. The Journals of Geronotoloy: Series B: Psychological 
Sciences and Social Sciences, 58B, 153-165. 
Murphy, S. E., Yiend, J., Lester, K. J., Cowen, P. J., & Harmer, C. J. (2009). Short-term  
serotonergic but not noradrenergic antidepressant administration reduces attentional 
vigilance to threat in healthy volunteers. International Journal of 
Neuropsychopharmacology, 12, 169-179. 
Naragon-Gainey, K., Gallagher, M. W., & Brown, T.A . (2013). Stable “trait” variance of  
THE TREATMENT OF NEUROTISCM 23 
temperament as a predictor of the temporal course of depression and social phobia. 
Journal of Abnormal Psychology, 122, 611-623. 
Quilty, L. C., Meusel, L. A., & Bagby, R. M. (2008). Neuroticism as a mediator of treatment 
response to SSRIs in major depressive disorder. Journal of Affective Disorders, 111, 67-
73. doi:10.1016/j.jad.2008.02.006 
Payne, L. A., Ellard, K. K., Farchione, T.J., Fairholme, C. P., & Barlow, D. H. (2014). Emotional  
 
disorders: A unified transdiagnostic protocol. In D.H. Barlow (Ed.), Clinical handbook of  
psychological disorders: A step-by-step treatment manual (5th ed.). New York, NY: The  
Guilford Press. 
Rapee, R. M., Kennedy, S. J., Ingram, M., Edwards, S. L., & Sweeney, L. (2010). Altering the 
trajectory of anxiety in at-risk young children. The American Journal of Psychiatry, 167, 
1518-1525. doi:10.1176/appi.ajp.2010.09111619 
Rapee, R. M., Kennedy, S., Ingram, M., Edwards, S., & Sweeney, L. (2005). Prevention and 
early intervention of anxiety disorders in inhibited preschool children. Journal of 
Consulting and Clinical Psychology, 73, 488-497. doi:10.1037/0022-006X.73.3.488 
Roberts, B. W., & Mroczeck, D. (2008). Personality trait change in adulthood. Current  
Directions in Psychological Science, 17, 31-35. doi:10.1111/j.1467-8721.2008.00543.x 
Roberts, B. W., Walton, K. E., & Viechtbauer, W. (2006). Patterns of mean-level change in 
personality traits across the life course: A meta-analysis of longitudinal studies. 
Psychological Bulletin, 132, 1-25. doi:10.1037/0033-2909.132.1.1 
Rosen, J. B., & Schulkin, J. (1998). From normal fear to pathological anxiety. Psychological 
Review,105, 325-350. doi:10.1037/0033-295X.105.2.325 
Sauer-Zavala, S., Bentley, K. H., Wilner, J. G., & Barlow, D. H. (2015). Transdiagnostic  
THE TREATMENT OF NEUROTISCM 24 
 treatment of borderline personality disorder and comorbid disorders: A clinical  
 replication series. Journal of Personality Disorders, 29, 179. 
Sauer-Zavala, S. & Barlow, D.H. (2014). The case for borderline personality disorder as an  
emotional disorder: Implications for Treatment. Clinical Psychology: Science and 
Practice. 21, 118-138 
Segal, Z., Teasdale, J., Williams, M. (2002). Mindfulness-Based cognitive therapy for  
depression. New York: Guilford Press 
Shipley, B.A., Weiss, A., Der., G., Taylor, M.D., Deary, I.J. (2007). Neuroticism, extraversion, 
and mortality in the UK Health and Lifestyle Survey: a 21-Year prospective cohort study. 
Psychosocial Medicine, 69, 923-931.doi: 10.1097/PSY.0b013e31815abf83  
Small, B. J., Hertzog, C., Hultsch, D. F., & Dixon, R. A. (2003). Stability and change in adult 
personality of 6 years: Findings from the Victoria Longitudinal Study. The Journals of 
Gerontology: Series B: Psychological Sciences and Social Sciences, 58B, 166-176. 
doi:10.1093/geronb/58.3.P166 
Smith, T.W., & MacKenzie, J. (2006). Personality and risk of physical illness. Annual Review of 
Clinical Psychology, 2, 435-467. doi: 10.1146/annurev.clinpsy.2.022305.095257 
Stein, M. B., Simmons, A. N., Feinstein, J. S., & Paulus, M. P. (2007). Increased amygdala and 
insula activation during emotion processing in anxiety-prone subjects. The American 
Journal of Psychiatry, 164, 318-327. doi:10.1176/appi.ajp.164.2.318 
Soskin, D. P., Carl, J. R., Alpert, J., & Fava, M. (2012). Antidepressant effects on emotional 
temperament: Toward a biobehavioral research paradigm for major depressive disorder. 
CNS Neuroscience & Therapeutics, 18, 441-451. doi:10.1111/j.1755-5949.2012.00318.x 
THE TREATMENT OF NEUROTISCM 25 
Spijker, J., de Graf, R., Oldehinkel, A. J., Nolen, W. A., & Ormel, J. (2007). Are the 
vulnerability effects of personality and psychosocial functioning on depression accounted 
for by subthreshold symptoms? Depression and Anxiety, 24, 472-478. 
doi:10.1002/da.20252 
Stein, M. B., Simmons, A. N., Feinstein, J. S., & Paulus, M. P. (2007). Increased amygdala and 
insula activation during emotion processing in anxiety-prone subjects. The American 
Journal of Psychiatry, 164, 318-327. doi:10.1176/appi.ajp.164.2.318 
Suls, J., & Bunde, J. (2005). Anger, anxiety, and depression as risk factors for cardiovascular 
disease: The problems and implications of overlapping affective dispositions. 
Psychological Bulletin, 131, 260-300. doi: 10.1037/0033-2909.131.2.260 
Tang, A.C., Reeb-Southerland, B.C., Romeo, R.D., & McEwen, B.S. (2012). Reducing 
behavioral inhibition to novelty via systematic neonatal novelty exposure: The influence 
of matern hypthalamic-pituatiary-adrenal regulation. Biological Psychiatry, 72, 150-156. 
doi: 10.1016/j.biopsych.2012.03.021 
Tang, T. Z., DeRubeis, R. J., Hollon, S. D., Amsterdam, J., Shelton, R., & Schalet, B. (2009).  
Personality change during depression treatment: A placebo-controlled trial. Archives of 
General Psychiatry, 66, 1322-1330. doi:10.1001/archgenpsychiatry.2009.166 
Tomarken, A. J., Dichter, G. S., Freid, C., Addington, S., & Shelton, R.C. (2004). Assessing the  
effects of bupropion SR on mood dimensions of depression. Journal of Affective 
Disorders, 78, 235-241. doi:10.1016/S0165-0327(02)00306-3 
Weinstock, L.M., & Whisman, M.A. (2006). Neuroticism as a common feature of the depressive 
and anxiety disorders: A test of the revised integrative hierarchical model in a national 
sample. Journal of Abnormal Psychology, 115, 68-74.doi: 10.1037/0021-843X.115.1.68 
THE TREATMENT OF NEUROTISCM 26 
Westlye, L. T., Bjornebekk, A., Grydeland, H., Fjell, A. M., & Walhovd, K. B. (2011). Linking 
an anxiety-related personality trait to brain white matter microstructure: diffusion tensor 
imaging and harm avoidance. Archives of General Psychiatry, 68, 369-377. 
doi:10.1001/archgenpsychiatry.2011.24 
Widiger, T., Trull, T., Clarkin, J., Sanderson, C., & Costa, P. (2002) A description of the DSM- 
IV personality disorders with the five-factor model of personality. In P. Costa & T.  
Widiger (Eds.) Personality disorders and the five-factor model of personality ( 2nd ed.,  
pp.89-99). Washington, DC: American Psychological Association. doi: 10.1037/10423- 
006 
Widiger, T. A., Verheul, R., & van den Brink, W. (1999). Personality and psychopathology. In 
L. A. Pervin & O. P. John (Eds.), Handbook of personality: Theory and research (2nd ed., 
pp. 347-366). New York, NY: Guilford Press. 
Zanarini, M., Frankenburg, F., Dubo, E., Sickel, E., Trikha, A., Levin, A., & Reynolds, V.  
(1998). Axis II comorbidity of borderline personality disorder, Comprehensive  
Psychiatry, 39, 296-302. doi:10.1016/S0010-440X(98)90038-4 
 
 
